These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34678527)

  • 21. Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.
    Haftmann RJ; Pineda EM; Hall BA; Wilson MD; Mateev SN
    J Pediatr Pharmacol Ther; 2023; 28(3):228-234. PubMed ID: 37303766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
    Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
    Byun JH; Jang IS; Kim JW; Koh EH
    Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
    Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
    Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standardization of Anti-Xa Assay and its Comparison with Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin Therapy.
    Thalappil V; Anand J; Keepanasseril A; Kar R
    Indian J Hematol Blood Transfus; 2024 Jul; 40(3):432-436. PubMed ID: 39011243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients.
    Isherwood M; Murphy ML; Bingham AL; Siemianowski LA; Hunter K; Hollands JM
    J Thromb Thrombolysis; 2017 May; 43(4):476-483. PubMed ID: 28070821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism.
    Zhu E; Yuriditsky E; Raco V; Katz A; Papadopoulos J; Horowitz J; Maldonado T; Ahuja T
    Int J Lab Hematol; 2024 Apr; 46(2):354-361. PubMed ID: 37989523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
    Bhatt MD; Paes BA; Chan AK
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Use of Unfractionated Heparin with Intra-Aortic Balloon Counterpulsation.
    Nuti O; Merchan C; Papadopoulos J; Horowitz J; Rao SV; Ahuja T
    Heart Lung Circ; 2024 Jul; 33(7):975-982. PubMed ID: 38575436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 36. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
    Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.
    May JE; Siniard RC; Taylor LJ; Marques MB; Gangaraju R
    Am J Clin Pathol; 2022 Mar; 157(3):321-327. PubMed ID: 34562001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
    Toulon P; Smahi M; De Pooter N
    J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?
    Coene KLM; van der Graaf F; van de Kerkhof D
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):164-171. PubMed ID: 27856667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.